-amyloid (Ab)-dependent neuronal hyperactivity is believed to contribute to the circuit dysfunction that characterizes the early stages of Alzheimer's disease (AD). Although experimental evidence in support of this hypothesis continues to accrue, the underlying pathological mechanisms are not well understood. In this experiment, we used mouse models of Ab-amyloidosis to show that hyperactivation is initiated by the suppression of glutamate reuptake. Hyperactivity occurred in neurons with preexisting baseline activity, whereas inactive neurons were generally resistant to Ab-mediated hyperactivation. Ab-containing AD brain extracts and purified Ab dimers were able to sustain this vicious cycle. Our findings suggest a cellular mechanism of Ab-dependent neuronal dysfunction that can be active before plaque formation.
T he progressive buildup of b-amyloid (Ab) in the brains of Alzheimer's disease (AD) patients is a firmly established experimental observation (1, 2) . The consequences of this buildup are manifold and include synaptic dysfunction, inflammation, and, ultimately, cell death (3, 4) . On the systems level, functional brain changes such as impaired neuronal activity and disturbed brain metabolism have been associated with Ab amyloidosis (5) (6) (7) . Several lines of evidence indicate that neuronal hyperactivity is a potential key feature of early stages of AD. Both in mice and man, there is strong evidence of excessive neuronal activation that, under certain conditions, can induce epileptic seizures (8) (9) (10) . Functional imaging studies in individuals with prodromal AD reveal increased neuronal activity in the hippocampus and some neocortical areas (6) . The cellular correlates of this hyperactivity have been studied in mouse models of Ab amyloidosis by using two-photon calcium imaging (11, 12) and implicate an essential role for soluble Ab (11) .
An open question for understanding AD pathology is how soluble Ab mediates cellular dysfunction such as hyperactivity. A large number of possible Ab "receptors" have been suggested (13) , but their roles in neuronal dysfunction in vivo have not been elucidated. Ample evidence indicates an Ab-dependent impairment at both inhibitory (5, 8, 10 ) and excitatory (14) (15) (16) (17) synapses. Specifically, an impairment of glutamate homeostasis is evident in rodents (18) (19) (20) (21) and humans (22, 23) and might underlie the disturbed plasticity of hippocampal synapses (18, 19) . However, the link between impaired glutamate homeostasis and neuronal function in vivo is unclear. Here, we explored the mechanism of Ab-dependent neuronal hyperactivation and the forms of soluble Ab that mediate this cellular dysfunction.
Neuronal hyperactivity requires preexisting baseline activity
We used two-photon Ca 2+ imaging of hippocampal CA1 neurons in vivo (11) (fig. S1 , A to C) to test the direct action of soluble Ab. Synthetic Ab(1 to 40)S26C, in which the naturally occurring serine at position 26 was replaced with cysteine, was used to produce and test the effects of the disulfide cross-linked dimer [AbS26C] 2 (24, 25) .
[AbS26C] 2 was pressure-applied near the CA1 hippocampal pyramidal layer of 1-to 2-month-old wild-type (WT) mice. In most neurons, application of 500 nM [AbS26C] 2 reversibly induced a massive increase in activity, similar to the hyperactivity seen in amyloid precursor protein (APP) transgenic mice (11) (Fig. 1A , control experiments in fig. S1 , D and E). Applications of [AbS26C] 2 were ineffective in hippocampal slices (Fig. 1B  and fig. S2, A and B) . A possible explanation for these apparently contradictory findings was that the neuronal baseline activity was greatly reduced in hippocampal slices compared with that in vivo ( fig. S2, C and D) . In this experiment, to test the role of baseline activity for Ab-induced neuronal hyperactivation, we performed loss-of-(dys)function experiments in the hippocampus of WT mice in vivo and gain-of-(dys)function experiments in hippocampal slices. First, we demonstrated that application of [AbS26C] 2 was ineffective when blocking in vivo neuronal activity by antagonists ionotropic glutamate receptors (Fig. 1, C and E) or by the sodium-channel antagonist tetrodotoxin ( fig. S3 ). Next, we turned to the analysis of hippocampal slices in vitro and did opposite experiments in which we induced in vivo-like baseline activity through various pharmacological manipulations. Treatments included (i) block of g-aminobutyric acid-mediated synaptic inhibition by bicuculline, (ii) addition of glutamate to the bath, (iii) elevation of the extracellular K + concentration, and (iv) combinations of these manipulations. Each of these treatments induced an average baseline activity that was similar to that detected under in vivo conditions ( fig. S4A ). Baseline activity increased in the presence of bicuculline in five representative neurons, as illustrated in Fig. 1D , left. In these conditions, the application of [AbS26C] 2 resulted in a reversible increase of additional activity (Fig. 1, D and F) . A similar effect was observed by the addition of low levels of glutamate (Fig. 1G) or by the elevation of the extracellular potassium concentration (Fig. 1H , and controls are shown in fig. S4 , B and D). In studies on the Ab dependence of activity-dependent synaptic plasticity, such as long-term potentiation (LTP) [for example, (19, 24) ] or long-term depression [for example, (18, 26) ], an increase of baseline activity is probably not necessary, because the induction protocols for synaptic plasticity involve increased levels of activity. In conclusion, our in vitro experiments support the in vivo observations and indicate that increased levels of baseline activity are a prerequisite for [AbS26C] 2 -induced hyperactivity. Cell-by-cell analyses show that, despite a considerable variance, there is, on average, a positive correlation between baseline activity and the degree of hyperactivation ( Fig. 1I and fig. S4E ).
Hyperactivation through an Ab-dependent block of glutamate reuptake Under in vivo conditions, neuronal activity generated by glutamatergic excitation was required for [AbS26C] 2 -induced hyperactivity (Fig. 1C) . In our search for a cause underlying a synaptic potentiation, we considered pre-and postsynaptic mechanisms. To investigate whether [AbS26C] 2 acted presynaptically, we performed paired-pulse facilitation experiments tested for possible changes of presynaptic release probability of glutamate (27) . Application of [AbS26C] 2 had no detectable impact on paired-pulse facilitation ( fig. S5 ), as expected (18, 24, 28 ). An alternative hypothesis was inspired by reports on an Ab-dependent defect of the glutamate homeostasis, possibly involving an impairment of glutamate reuptake (18) (19) (20) . In a first step, we tested whether pharmacologically blocking glutamate uptake in vivo had any detectable effect on neuronal activity. For this, we used the unspecific glutamate uptake blocker DL-threo-b-benzyloxyaspartic acid (TBOA), which can mimic some effects of Ab on activity-dependent synaptic plasticity in vitro (18, 19) . The local application of TBOA to hippocampal CA1 neurons in WT mice induced neuronal hyperactivity (Fig. 2 , A and B), an effect that was similar to that observed with [AbS26C] 2 applications (Figs. 1, A and E, and 2C). Nevertheless, [AbS26C] 2 and TBOA may have exerted their actions through different mechanisms. To address this issue, we repeated the experiments in the transgenic APP23 × PS45 mouse model of Ab-amyloidosis (12) . We used young mice with no obvious amyloid plaques but with high levels of soluble Ab (12) and pronounced hippocampal hyperactivity (11) (Fig. 2, D and E, and fig. S6 ). Application of TBOA had strong hyperactivating action in WT mice ( Fig. 2F ) but almost no effect in APP23 × PS45 mice (Fig. 2 into the hippocampal CA1 region in vivo (Fig. 3A) , leading after 3 weeks to a strong and dense neuronal expression of iGluSnFr (Fig. 3B ). In parallel, we also performed as controls sparse-labeling experiments of CA1 pyramidal neurons (Fig. 3C ). To induce synaptic glutamate release, we electrically stimulated a bundle of afferent Schaffer collateral axons in hippocampal slices. We performed twophoton glutamate imaging and collected the bulk response in a region of interest (Fig. 3D, inset) , which covered a substantial part of the glutamate sensor-expressing dendrites of CA1 neurons (Fig.  3C ). Single-shock stimulation evoked large transient increases in extracellular glutamate concentration ( fig. S7A , and control experiments are shown in fig. S7 , B and C). Local application of Ab produced a strong and reversible potentiation of the glutamate transients (Fig. 3, D and E, and  fig. S7D ). Similar glutamate transients were induced by applications of TBOA (Fig. 3, F fig. S9, A  and B) . Furthermore, the cross-linking GLT-1 antibody (GLT-1 AB) also induced hyperactivity (Fig.  3, H and I, and controls are shown in fig. S9, C and  D) . Cross-linking GLT-1 ABs can impair glutamate uptake by obstructing lateral membrane diffusion of glutamate-GLT-1 complexes along astrocytic protrusions out of the synaptic cleft, a process suggested to be essential for clearing synaptically released glutamate (31). Our results using DHK, GLT-1, and Ab suggest that the Ab-dependent block of glutamate reuptake may involve not Ab binding to transporter proteins but rather Zott 
perturbation of astrocytic membrane dynamics and obstruction of GLT-1 diffusion (31).

Effectiveness of human Ab species derived from Alzheimer's patients
To further explore the relevance of our findings to the human disease, we employed forms of Ab derived from AD brain. First, we used Abcontaining AD brain extracts (32) . When examined by immunoprecipitation and immunoblotting, the Ab in such brain extracts migrates on denaturing SDS-polyacrylamide gel electrophoresis with molecular weights indicative of monomers and SDSstable dimers. Ab-containing AD extracts (Fig. 4A) , but not those immunodepleted of Ab (ID extract, Fig. 4B ), are capable of inducing a variety of disease-relevant effects (24, (33) (34) (35) . In vivo local applications of AD extract to CA1 neurons of WT mice produced a marked neuronal hyperactivity (Fig. 4 , C, D, and F), whereas the ID extract did not induce hyperactivity ( fig. S10, A and B) . Similarly, when tested in vitro, AD extract induced hyperactivity in active hippocampal CA1 neurons treated with bicuculline (Fig. 4 , E and G), but ID extract had no effect ( fig. S10, C and D) . Purified AD brain-derived cross-linked dimers can block LTP and impair neuritic integrity (36) . We thus investigated whether such material (fig. S11A) could also induce hyperactivity. As a control, we isolated Ab monomer from the same AD brain ( fig. S11A ). Ab dimers, but not equimolar Ab monomers (36, 37) (fig. S11 , B to E), reduced neurite length ( fig. S11 , B and C) and the number of branch points (fig. S11, D and E) . Similarly, the application of brain-derived Ab dimers effectively but reversibly induced hyperactivity in WT mice in vivo (Fig. 5, A and B) . Human Ab dimers induced similar levels of hyperactivity at substantially lower concentrations than the synthetic ones (0.2 mg/ml human versus 4. dimers). The application of human Ab monomers had little or no effect (Fig. 5E ). The activity of dimers was highly dose-dependent, with an apparent median effective concentration of 27.5 ng/ml (Fig. 5C) . Application of AD brain-derived Ab dimers to bicuculline-treated mouse hippocampal slices reliably induced hyperactivity in neurons with high baseline activity ( fig. S12 ) and produced an activity-dependent hyperactivation in vivo (Fig. 5D) . Finally, when Ab monomers were applied to hippocampal CA1 neurons, they had little or no ability to induce both in vivo and in vitro ( fig. S13 ).
Discussion and conclusions
In this study, we characterized rapid actions of synthetic and AD brain-derived Ab on the activity of mouse hippocampal neurons in vitro and in vivo. Our findings suggest that Ab can induce hyperexcitation in sensitive neurons and that this drives a vicious cycle of hyperactivation (Fig.  5F ). To explain the scheme, we begin with the insight that a simple solution exists for the puzzle that Ab-dependent hyperactivity is readily observed in vivo but not in vitro. We were able to show that there is an absolute need of ongoing activity for the induction of Ab-dependent synaptic hyperactivation. Next, the block of synaptically released glutamate at active excitatory synapses is an important element of the vicious cycle. The third component of the cycle is excessive perisynaptic accumulation of glutamate. The final element of the cycle is revealed by the dependence of the increase in hyperactivation on the level of baseline activity, both for synthetic and human brainderived Ab dimers. This process of amplification appears to be self-limited at high levels of hyperactivity, as indicated by the results of the occlusion experiments. Thus, multiple lines of evidence underscore the role of all four elements of the cycle. Although the dependence of hyperactivation on impaired excitatory synaptic transmission involving defective glutamate reuptake had not previously been predicted, there is prior evidence for impaired glutamate homeostasis in both rodents (18) (19) (20) (21) and AD patients (22, 23) . Furthermore, there is evidence for beneficial effects of certain antiglutamatergic drugs, such as memantine, against AD (20, (38) (39) (40) . It is suggested that these drugs may act perisynaptically on extrasynaptic NMDA receptors (40) . Moreover, this process may be aggravated by pathologically reduced expression levels of glutamate transporters, such as EAAT2 in AD patients (22) , or by reduced levels of synaptic inhibition (5, 8, 10) . Finally, Abdependent hyperactivity precedes plaque formation and is present at early stages, long before 5 of 7 overt clinical symptoms of AD (6) . A gradual neuronal "silencing" occurs after plaques are formed and may be the prelude to neurodegeneration (41) . Although functional deficits of circuits caused by massive neuronal degeneration are nearly impossible to be repaired with current approaches, it may be possible to therapeutically target hyperactivation at early stages of the disease by lowering Ab levels, reducing neuronal activity by enhancing synaptic inhibition, or by pharmacologically manipulating EAATs.
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